Buzas, et. al (Published in the American Journal of Hospital System Pharmacists, 2022) curated a 552,707 patient-day study that found a 48% reduction in occlusions with the single intervention of the TKO Anti-reflux technology.
Buzas, et. al (Published in the American Journal of Hospital System Pharmacists, 2022) curated a 552,707 patient-day study that found a 48% reduction in occlusions with the single intervention of the TKO Anti-reflux technology.